Search results
Q1 2024 CytomX Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 7 days agoAnd our current clinical pipeline is really gaining momentum. And we have a very exciting 12 to 24 months ahead of us. Moving now to our T-cell engager strategy. T-
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
WTNH-TV New Haven· 2 days agoOf utmost importance, we remain on track to submit our BLA in the second half of 2024 under the accelerated approval pathway for INO-3107 as a treatment for RRP and are working ...
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit...
Benzinga· 6 hours agoLOS ANGELES, Ca., May 15, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming June 4, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 days agoCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript May 8, 2024 CytomX...
Exploring Three Swedish Growth Companies With High Insider Ownership On The Swedish Exchange
Simply Wall St. via Yahoo Finance· 22 hours agoAs global markets show signs of resilience, with indices like the S&P 500 nearing record highs,...
DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its...
Benzinga· 1 day agoThe analyst writes that the FDA considered lead program INO-3107 Phase 1/2 clinical trials sufficient for the Accelerated Approval Program. If approved, INO-3107 could be the first non-surgical ...
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
WPRI Providence· 3 days agoThe volume of data being presented by Astellas reinforces its commitment to changing the course of cancer treatment through targeted therapies for hard-to-treat cancers like ...
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination...
Benzinga· 2 days agoOSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 days agoPhotocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China PR Newswire OSLO, Norway, May 12, 2024 OSLO, Norway, May 12, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company,
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 4 hours agoFortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA accepted New Drug Application filing for DFD-
